Cancer BiologyCell Death and DiseasePeer-reviewed
Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression
Sk. Kayum Alam, Anuradha Pandit, Li Wang…·Luke H. Hoeppner
This study shows that dopamine D2 receptor agonists reduce angiogenesis and inhibit chemotherapy-refractory small cell lung cancer progression by targeting tumour-associated endothelial cells.
17 citationstop 4%